Limits...
Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience.

Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F - Oncotarget (2015)

Bottom Line: PS, number of cycles, baseline CA 19-9 and LDH serum levels, were found to be significantly related to OS.The multivariate analysis showed that both number of cycles (HR = 9.14, 95% CI 1.84-45.50, p = 0.001) and PS (HR = 13.18, 95% CI 2.73-63.71, p = 0.001) were independently associated with OS.NAB-P/GEM regimen should be used in all patients with advanced or metastatic PC, with the exception of those with serious contraindications to chemotherapy, such as severe renal or hepatic impairment or major cardiovascular diseases.

View Article: PubMed Central - PubMed

Affiliation: Oncology Unit, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy.

ABSTRACT

Purpose: The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic factors influencing overall survival (OS).

Experimental design: Patients with age < 85 years, ECOG-performance status (PS) < 3, and adequate renal, hepatic and hematologic function were eligible. NAB-P (125 mg/m2) and GEM (1000 mg/m2) day 1,8,15 every 4 weeks were employed for 3-6 cycles or until highest response.

Results: Overall, 147 cycles (median 4, range 1-11 cycles) were administered on thirty-seven consecutive patients (median 66 years old, range 40-82) treated. The median overall progression-free survival and OS were 6.2 and 9.2 months, respectively. The G 3-4 dose-limiting toxicity were neutropenia (20.7%), severe anemia (17.2%), and cardiovascular toxicity (10.3%). PS, number of cycles, baseline CA 19-9 and LDH serum levels, were found to be significantly related to OS. The multivariate analysis showed that both number of cycles (HR = 9.14, 95% CI 1.84-45.50, p = 0.001) and PS (HR = 13.18, 95% CI 2.73-63.71, p = 0.001) were independently associated with OS.

Conclusion: NAB-P/GEM regimen should be used in all patients with advanced or metastatic PC, with the exception of those with serious contraindications to chemotherapy, such as severe renal or hepatic impairment or major cardiovascular diseases.

No MeSH data available.


Related in: MedlinePlus

Overall survival(A) and progression-free survival (B) of the overall population.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4480749&req=5

Figure 1: Overall survival(A) and progression-free survival (B) of the overall population.

Mentions: We obtained complete response in three (10.3%) and partial response in four (13.8%) out of 29 evaluable patients, whilst 16 (55.2%) and six (20.7%) patients had stable disease or progressive disease, respectively. The overall objective response rate and disease control rate were 19% (95% CI, 8%–30%) and 62% (95% CI, 55%–69%), respectively, and the median duration of response was 8 months (range 1–9 months). The median overall progression-free survival (PFS) and OS were 6.2 and 9.2 months, respectively (Figure 1A–1B). The grade (G) 3–4 dose-limiting toxicity were neutropenia in six (20.7%), severe anemia in five (17.2%), thrombocytopenia in two (6.9%), signs and symptoms of neurological and cardiovascular toxicity in three (10.3%) and one (3.4%) patients, respectively. One more patient (3.4%) complained of fatigue. Eight (21.6%) patients were not evaluable for early suspension.


Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience.

Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F - Oncotarget (2015)

Overall survival(A) and progression-free survival (B) of the overall population.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4480749&req=5

Figure 1: Overall survival(A) and progression-free survival (B) of the overall population.
Mentions: We obtained complete response in three (10.3%) and partial response in four (13.8%) out of 29 evaluable patients, whilst 16 (55.2%) and six (20.7%) patients had stable disease or progressive disease, respectively. The overall objective response rate and disease control rate were 19% (95% CI, 8%–30%) and 62% (95% CI, 55%–69%), respectively, and the median duration of response was 8 months (range 1–9 months). The median overall progression-free survival (PFS) and OS were 6.2 and 9.2 months, respectively (Figure 1A–1B). The grade (G) 3–4 dose-limiting toxicity were neutropenia in six (20.7%), severe anemia in five (17.2%), thrombocytopenia in two (6.9%), signs and symptoms of neurological and cardiovascular toxicity in three (10.3%) and one (3.4%) patients, respectively. One more patient (3.4%) complained of fatigue. Eight (21.6%) patients were not evaluable for early suspension.

Bottom Line: PS, number of cycles, baseline CA 19-9 and LDH serum levels, were found to be significantly related to OS.The multivariate analysis showed that both number of cycles (HR = 9.14, 95% CI 1.84-45.50, p = 0.001) and PS (HR = 13.18, 95% CI 2.73-63.71, p = 0.001) were independently associated with OS.NAB-P/GEM regimen should be used in all patients with advanced or metastatic PC, with the exception of those with serious contraindications to chemotherapy, such as severe renal or hepatic impairment or major cardiovascular diseases.

View Article: PubMed Central - PubMed

Affiliation: Oncology Unit, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy.

ABSTRACT

Purpose: The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic factors influencing overall survival (OS).

Experimental design: Patients with age < 85 years, ECOG-performance status (PS) < 3, and adequate renal, hepatic and hematologic function were eligible. NAB-P (125 mg/m2) and GEM (1000 mg/m2) day 1,8,15 every 4 weeks were employed for 3-6 cycles or until highest response.

Results: Overall, 147 cycles (median 4, range 1-11 cycles) were administered on thirty-seven consecutive patients (median 66 years old, range 40-82) treated. The median overall progression-free survival and OS were 6.2 and 9.2 months, respectively. The G 3-4 dose-limiting toxicity were neutropenia (20.7%), severe anemia (17.2%), and cardiovascular toxicity (10.3%). PS, number of cycles, baseline CA 19-9 and LDH serum levels, were found to be significantly related to OS. The multivariate analysis showed that both number of cycles (HR = 9.14, 95% CI 1.84-45.50, p = 0.001) and PS (HR = 13.18, 95% CI 2.73-63.71, p = 0.001) were independently associated with OS.

Conclusion: NAB-P/GEM regimen should be used in all patients with advanced or metastatic PC, with the exception of those with serious contraindications to chemotherapy, such as severe renal or hepatic impairment or major cardiovascular diseases.

No MeSH data available.


Related in: MedlinePlus